Enhancer binding protein (EBP1) makes base and backbone contacts over one complete turn of the DNA double helix.

PubWeight™: 1.19‹?› | Rank: Top 10%

🔗 View Article (PMID 2544731)

Published in J Mol Biol on April 20, 1989

Authors

L Clark1, J Nicholson, R T Hay

Author Affiliations

1: Department of Biochemistry and Microbiology, University of St. Andrews, Fife, Scotland.

Articles citing this

Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res (1992) 3.22

Inhibition of NF-kappaB DNA binding by nitric oxide. Nucleic Acids Res (1996) 1.94

Molecular characterization of the GCN4-DNA complex. Proc Natl Acad Sci U S A (1990) 1.82

Domain organization of I kappa B alpha and sites of interaction with NF-kappa B p65. Mol Cell Biol (1995) 1.44

Role of cysteine62 in DNA recognition by the P50 subunit of NF-kappa B. Nucleic Acids Res (1993) 1.43

The SV40 TC-II(kappa B) enhanson binds ubiquitous and cell type specifically inducible nuclear proteins from lymphoid and non-lymphoid cell lines. EMBO J (1989) 1.34

The SV40 TC-II(kappa B) and the related H-2Kb enhansons exhibit different cell type specific and inducible proto-enhancer activities, but the SV40 core sequence and the AP-2 binding site have no enhanson properties. EMBO J (1989) 1.26

Interaction of enhancer-binding protein EBP1 (NF-kappa B) with the human immunodeficiency virus type 1 enhancer. J Virol (1990) 1.22

S-adenosyl methionine alters the DNA contacts of the EcoKI methyltransferase. Nucleic Acids Res (1995) 0.87

Conformational changes induced by DNA binding of NF-kappa B. Nucleic Acids Res (1995) 0.83

DNA binding alters the protease susceptibility of the p50 subunit of NF-kappa B. Nucleic Acids Res (1993) 0.82

Transcriptional enhancer related DNA sequences: anomalous 1H NMR NOE crosspeaks. Nucleic Acids Res (1992) 0.81

Analysis of the significance of two single-base-pair differences in the SL3-3 and Akv virus long terminal repeats. J Virol (1991) 0.81

I(kappa)B(gamma) inhibits DNA binding of NF-kappaB p50 homodimers by interacting with residues that contact DNA. Mol Cell Biol (1996) 0.78

A new interference footprinting method for analysing simultaneously protein contacts to phosphate and guanine residues on DNA. Nucleic Acids Res (1995) 0.75

Articles by these authors

Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science (1990) 8.91

SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol Cell (1998) 6.62

A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes. Mol Cell (2000) 6.14

Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J Biol Chem (2001) 5.04

SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J Biol Chem (2000) 4.96

Y-chromosomal diversity in Europe is clinal and influenced primarily by geography, rather than by language. Am J Hum Genet (2000) 4.72

Initiation of SV40 DNA replication in vivo: location and structure of 5' ends of DNA synthesized in the ori region. Cell (1982) 4.50

SUMO-1 modification activates the transcriptional response of p53. EMBO J (1999) 4.19

Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res (1992) 3.22

Variations in behavior and condition of a Southern Ocean top predator in relation to in situ oceanographic conditions. Proc Natl Acad Sci U S A (2007) 3.04

Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med (1999) 3.03

Ubch9 conjugates SUMO but not ubiquitin. FEBS Lett (1997) 2.73

Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol (2000) 2.72

Inducible nuclear expression of newly synthesized I kappa B alpha negatively regulates DNA-binding and transcriptional activities of NF-kappa B. Mol Cell Biol (1995) 2.69

SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. J Cell Sci (1999) 2.46

Nuclear localization of I kappa B alpha promotes active transport of NF-kappa B from the nucleus to the cytoplasm. J Cell Sci (1997) 2.44

An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene (2000) 2.36

Estimating Scandinavian and Gaelic ancestry in the male settlers of Iceland. Am J Hum Genet (2000) 2.22

Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1. J Biol Chem (1999) 2.18

Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 T lymphocytes. EMBO J (1995) 2.10

Proteolytic degradation of MAD3 (I kappa B alpha) and enhanced processing of the NF-kappa B precursor p105 are obligatory steps in the activation of NF-kappa B. Nucleic Acids Res (1993) 2.08

Nuclear retention of IkappaBalpha protects it from signal-induced degradation and inhibits nuclear factor kappaB transcriptional activation. J Biol Chem (1999) 2.05

zeta PKC induces phosphorylation and inactivation of I kappa B-alpha in vitro. EMBO J (1994) 1.95

Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IkappaB alpha/NF-kappaB pathway in limb-girdle muscular dystrophy type 2A. Nat Med (1999) 1.94

Inhibition of NF-kappaB DNA binding by nitric oxide. Nucleic Acids Res (1996) 1.94

Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene (1999) 1.93

The origin of adenovirus DNA replication: minimal DNA sequence requirement in vivo. EMBO J (1985) 1.89

European Y-chromosomal lineages in Polynesians: a contrast to the population structure revealed by mtDNA. Am J Hum Genet (1998) 1.87

The adenovirus protease is activated by a virus-coded disulphide-linked peptide. Cell (1993) 1.86

Role of IkappaBalpha ubiquitination in signal-induced activation of NFkappaB in vivo. J Biol Chem (1996) 1.82

Properties of herpesvirus-induced "immediate early" polypeptides. Virology (1980) 1.75

'Active learning in the UK undergraduate dental course'. Br Dent J (1994) 1.71

Almost two centuries with amalgam: where are we today? J Am Dent Assoc (1994) 1.68

Replication of adenovirus mini-chromosomes. J Mol Biol (1984) 1.62

Genetic evidence for a family-based Scandinavian settlement of Shetland and Orkney during the Viking periods. Heredity (Edinb) (2005) 1.59

Antipeptide antisera define neutralizing epitopes on the adenovirus hexon. J Gen Virol (1992) 1.57

Delayed visual maturation: ophthalmic and neurodevelopmental aspects. Dev Med Child Neurol (1990) 1.55

Recognition of the adenovirus type 2 origin of DNA replication by the virally encoded DNA polymerase and preterminal proteins. EMBO J (1992) 1.52

Domain organization of I kappa B alpha and sites of interaction with NF-kappa B p65. Mol Cell Biol (1995) 1.44

Role of cysteine62 in DNA recognition by the P50 subunit of NF-kappa B. Nucleic Acids Res (1993) 1.43

Nasogastric drug administration. Prof Nurse (1998) 1.40

The adenovirus type 40 hexon: sequence, predicted structure and relationship to other adenovirus hexons. J Gen Virol (1989) 1.39

Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors. Am J Pathol (2001) 1.38

Activation of NF-kappaB by PM(10) occurs via an iron-mediated mechanism in the absence of IkappaB degradation. Toxicol Appl Pharmacol (2000) 1.36

Single incision laparoscopic surgery in general surgery: a review. Ann R Coll Surg Engl (2011) 1.36

DNA sequence of the adenovirus type 41 hexon gene and predicted structure of the protein. J Gen Virol (1988) 1.36

p75-mediated NF-kappaB activation enhances the survival response of developing sensory neurons to nerve growth factor. Mol Cell Neurosci (1999) 1.34

Interactions between the adenovirus type 2 DNA polymerase and the DNA binding domain of nuclear factor I. New Biol (1990) 1.33

An evaluation of accelerated Portland cement as a restorative material. Biomaterials (2002) 1.31

Identification of lysine residues required for signal-induced ubiquitination and degradation of I kappa B-alpha in vivo. Oncogene (1996) 1.30

Common properties of nuclear body protein SP100 and TIF1alpha chromatin factor: role of SUMO modification. Mol Cell Biol (2001) 1.29

Sequence requirement for specific interaction of an enhancer binding protein (EBP1) with DNA. Nucleic Acids Res (1989) 1.29

Co-operative interactions between NFI and the adenovirus DNA binding protein at the adenovirus origin of replication. EMBO J (1989) 1.28

Identification and purification of EBP1: a HeLa cell protein that binds to a region overlapping the 'core' of the SV40 enhancer. Genes Dev (1988) 1.27

Genetic abnormalities detected in ependymomas by comparative genomic hybridisation. Br J Cancer (2002) 1.26

NF-kappaB inhibits apoptosis in murine mammary epithelia. J Biol Chem (2000) 1.25

Expression of a foreign epitope on the surface of the adenovirus hexon. J Gen Virol (1994) 1.25

Inducible degradation of I kappa B alpha in vitro and in vivo requires the acidic C-terminal domain of the protein. Mol Cell Biol (1995) 1.24

Interaction of enhancer-binding protein EBP1 (NF-kappa B) with the human immunodeficiency virus type 1 enhancer. J Virol (1990) 1.22

Sequence specificity for the initiation of RNA-primed simian virus 40 DNA synthesis in vivo. J Mol Biol (1984) 1.22

Origin of adenovirus DNA replication. Role of the nuclear factor I binding site in vivo. J Mol Biol (1985) 1.21

Characterization of IkappaBalpha nuclear import pathway. J Biol Chem (1999) 1.20

NF-kappa B-dependent induction of the NF-kappa B p50 subunit gene promoter underlies self-perpetuation of human immunodeficiency virus transcription in monocytic cells. Proc Natl Acad Sci U S A (1992) 1.18

Persistent activation of nuclear factor-kappaB in cultured rat hepatic stellate cells involves the induction of potentially novel Rel-like factors and prolonged changes in the expression of IkappaB family proteins. Hepatology (1999) 1.17

Regulation of transcription factors by protein degradation. Cell Mol Life Sci (2000) 1.15

Nuclear factor I is specifically targeted to discrete subnuclear sites in adenovirus type 2-infected cells. J Virol (1992) 1.15

Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB. Oncogene (1998) 1.14

SUMO modification of the DEAD box protein p68 modulates its transcriptional activity and promotes its interaction with HDAC1. Oncogene (2007) 1.14

Cytokine-induced nuclear factor kappa B activation promotes the survival of developing neurons. J Cell Biol (2000) 1.10

Amiodarone and psychiatric symptoms. Br J Psychiatry (1999) 1.10

Interaction of the C-terminal region of p105 with the nuclear localisation signal of p50 is required for inhibition of NF-kappa B DNA binding activity. Nucleic Acids Res (1993) 1.07

Expression of the genome of potato leafroll virus: readthrough of the coat protein termination codon in vivo. J Gen Virol (1990) 1.06

Adenovirus DNA replication. Curr Top Microbiol Immunol (2003) 1.06

DNA sequences required for the initiation of adenovirus type 4 DNA replication in vitro. J Mol Biol (1988) 1.05

A cellular protein binds to a conserved sequence in the adenovirus type 2 enhancer. Nucleic Acids Res (1987) 1.04

Adenovirus DNA binding protein: helix destabilising properties. Nucleic Acids Res (1994) 1.03

Viable viruses with deletions in the left inverted terminal repeat define the adenovirus origin of DNA replication. J Gen Virol (1986) 1.01

A clinical evaluation of ophthalmic assessment in children with sensori-neural deafness. Child Care Health Dev (2003) 1.00

Procedurally similar competitive immunoassay systems for the serodiagnosis of Babesia equi, Babesia caballi, Trypanosoma equiperdum, and Burkholderia mallei infection in horses. J Vet Diagn Invest (2000) 1.00

Oral vs intravenous paracetamol for lower third molar extractions under general anaesthesia: is oral administration inferior? Br J Anaesth (2012) 0.99

Apoptin is modified by SUMO conjugation and targeted to promyelocytic leukemia protein nuclear bodies. Oncogene (2006) 0.99

Unemployment and child abuse. Br Med J (Clin Res Ed) (1987) 0.99

Domain organization of the adenovirus preterminal protein. J Virol (1997) 0.99

Activation of adenovirus-coded protease and processing of preterminal protein. J Virol (1994) 0.98

The carboxy-terminus of I kappaB alpha determines susceptibility to degradation by the catalytic core of the proteasome. Oncogene (1997) 0.96

Adenovirus subviral particles and cores can support limited DNA replication. J Gen Virol (1989) 0.95

Human immunodeficiency virus type 1 (HIV-1) viral protein R (Vpr) interacts with Lys-tRNA synthetase: implications for priming of HIV-1 reverse transcription. J Virol (1998) 0.94

Relationships between walk/run performance and cardiorespiratory fitness in adolescents who are overweight. Phys Ther (2001) 0.94

Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J Clin Oncol (2001) 0.94

Juvenile diabetes mellitus and the HLA system. Transplant Proc (1979) 0.94

Regulation of the DNA binding activity of NF-kappa B. Int J Biochem Cell Biol (1995) 0.93

An intervention programme to establish regular toothbrushing: understanding parents' beliefs and motivating children. Int Dent J (2000) 0.92

Interaction between hnRNPA1 and IkappaBalpha is required for maximal activation of NF-kappaB-dependent transcription. Mol Cell Biol (2001) 0.92

Aphid Acquisition and Cellular Transport of Potato leafroll virus-like Particles Lacking P5 Readthrough Protein. Phytopathology (2000) 0.91

Role of preterminal protein processing in adenovirus replication. J Virol (1997) 0.90

Identification of conserved residues contributing to the activities of adenovirus DNA polymerase. J Virol (2000) 0.90

Cephalic kinetics of intra-arterially injected lidocaine. Oral Surg Oral Med Oral Pathol (1977) 0.90

Replication of adenovirus type 4 DNA by a purified fraction from infected cells. Nucleic Acids Res (1991) 0.89